Regorafenib as Second-Line Systemic Therapy May Change the Treatment Strategy and Management Paradigm for Hepatocellular Carcinoma.
about
Molecular Targeted Agents for Hepatocellular Carcinoma: Current Status and Future Perspectives.Patient Selection for Transarterial Chemoembolization in Hepatocellular Carcinoma: Importance of Benefit/Risk Assessment.A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib.
P2860
Regorafenib as Second-Line Systemic Therapy May Change the Treatment Strategy and Management Paradigm for Hepatocellular Carcinoma.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Regorafenib as Second-Line Sys ...... for Hepatocellular Carcinoma.
@en
Regorafenib as Second-Line Sys ...... for Hepatocellular Carcinoma.
@nl
type
label
Regorafenib as Second-Line Sys ...... for Hepatocellular Carcinoma.
@en
Regorafenib as Second-Line Sys ...... for Hepatocellular Carcinoma.
@nl
prefLabel
Regorafenib as Second-Line Sys ...... for Hepatocellular Carcinoma.
@en
Regorafenib as Second-Line Sys ...... for Hepatocellular Carcinoma.
@nl
P2860
P356
P1433
P1476
Regorafenib as Second-Line Sys ...... for Hepatocellular Carcinoma.
@en
P2093
P2860
P304
P356
10.1159/000449335
P577
2016-09-14T00:00:00Z